Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
about
Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancerIntravesical electromotive drug administration for non-muscle invasive bladder cancerIntravesical bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancerIntravesical therapy for non-muscle invasive bladder cancer: a network meta-analysisHigh-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG ShortageIntravesical immunotherapy in nonmuscle invasive bladder cancerImmunotherapy for bladder cancer.Androgen deprivation therapy prevents bladder cancer recurrenceQuercetin-induced Growth Inhibition in Human Bladder Cancer Cells Is Associated with an Increase in Ca-activated K Channels.Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrenceRecurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette-Guerin: A single center experience and analysis of prognostic factors.Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis in human bladder cancer cells through mTOR/S6K1-mediated downregulation of Mcl-1Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1).Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity.Intravesical electromotive drug administration for non-muscle invasive bladder cancer.CD169-positive sinus macrophages in the lymph nodes determine bladder cancer prognosis.Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy.
P2860
Q24186083-EF6B795F-8813-47A6-B71A-75949E2543F6Q24187574-CCB241F3-FCB7-44E7-89C7-BD39A6302161Q24188295-B5F1D464-BBD7-4E8E-AA7A-328280F0E66DQ26471299-476195CB-1F0F-47F5-B575-900DFA511CFBQ26739003-B3DB7D0C-CFAD-4DEF-8550-01B96A7064A7Q26775979-7A1AD017-CB24-49C7-BDD4-0C4B18773204Q34477444-259677AF-E768-4EAB-8BB7-BF058CC28992Q35149647-326F566F-DE3C-4D0F-ADA3-87D43E2655F4Q35569357-E568AA1B-174D-4B09-B526-18577E9B41E8Q36362803-E5B48B76-152B-4346-8234-76EC3918313AQ37046554-6EB25257-AC15-4EDF-80F3-8E3DED44969AQ37094285-A2B457C4-424B-421F-8583-A49DD0E557EDQ37696178-F4ECFB38-855D-4571-9C45-9D2DD53B4320Q38345920-ACC10005-A506-441A-9002-29B3CB1E8F43Q38760463-A94F9000-AEA8-45D1-B913-5B43B2EA8733Q38924479-29A74F65-1792-4E0A-9F96-3149C3D79927Q46075170-88CCDD2F-0D63-41A5-AE47-622A6259A1CCQ47997127-4F56D7BD-68F2-4012-AD19-B8E84C29E585Q52665317-2390B76F-3E5C-47A7-8381-1B6B0525027DQ53098848-9A2BC22E-EB19-4D08-A0F6-CA8508323FB3
P2860
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
@ast
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
@en
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
@en-gb
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
@nl
type
label
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
@ast
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
@en
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
@en-gb
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
@nl
prefLabel
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
@ast
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
@en
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
@en-gb
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
@nl
P2093
P2860
P3181
P1476
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
@en
P2093
Jinhui Tian
Joey Kwong
Jun Qiang Tian
Pan Feng Shang
Zhi Ping Wang
Zhong Jin Yue
P2860
P3181
P356
10.1002/14651858.CD006885.PUB2
P577
2011-05-11T00:00:00Z